June 2026 Research Update

Across multiple studies, daratumumab was consistently linked to rapid improvement in blood markers of AL amyloidosis, and deeper blood responses tended to go along with longer survival. Heart responses were reported, but were less frequent than blood responses, especially in people starting with very advanced heart involvement. Overall, these results come mainly from retrospective (real-world) studies plus one small phase 2 trial, so some uncertainty remains about how well results compare across different centers and patient groups. [1] [2] [3]

In a large national real-world study of newly diagnosed patients in China, daratumumab-based frontline regimens led to faster and deeper blood responses than proteasome inhibitor-based regimens, and had higher heart response rates. In that same study, deeper blood responses and minimal residual disease (MRD) negativity were linked with longer event-free and overall survival, while combined liver and heart involvement marked a higher-risk subgroup. [1]

In a separate real-world cohort of newly diagnosed patients treated with daratumumab-based therapy, early response milestones mattered: better blood and heart responses at 3 months were tied to longer overall survival, and MRD negativity at 12 months further separated outcomes even among people who already reached a complete blood response. This study also noted that patients with the t(11;14) subtype had slower development of deep blood responses. [3]

For people with very advanced heart involvement, a phase 2 trial tested daratumumab alone in 40 newly diagnosed patients and reported a 6-month overall survival of 65% and a 6-month heart response rate of 30%. Serious complications were common in this high-risk group, including heart failure and sudden cardiac death, while quality of life remained stable during the study period. [2]

One additional report described outcomes for 51 patients with Mayo stage IIIb disease treated with daratumumab-based frontline therapy, but the summary provided here did not include specific response or survival numbers. [4]

Another paper evaluated venetoclax (a BCL-2 inhibitor) in advanced AL amyloidosis in a retrospective cohort, but no abstract or results were available in the materials provided, so its effectiveness and safety cannot be summarized here. [5]

For patients and caregivers, this month’s research mainly reinforces a practical message: when daratumumab-based therapy leads to a deep drop in the abnormal amyloid-forming proteins in the blood, people tend to do better over time, and MRD negativity may add extra information about risk even after a complete blood response. At the same time, the phase 2 trial focused on the sickest heart group shows that early months can still be dangerous despite fast blood responses, and heart improvement may lag behind. Evidence about venetoclax cannot be interpreted from the provided summary, so its role remains unclear based on this report alone. [1] [2] [3] [4] [5]

Across these studies, transplant-based care for amyloidosis was reported as feasible in carefully selected patients, with two main situations covered: autologous stem cell transplant for AL amyloidosis and heart transplant for severe amyloid heart disease. Overall, the reports describe low early mortality after autologous stem cell transplant in modern practice and durable outcomes in large cohorts, while heart transplant series highlighted survival that was similar across amyloid types but with substantial infection risk. Some factors measured before transplant (including heart strain markers, kidney function, and bone marrow plasma cell burden) were linked to worse outcomes, but the studies were retrospective and cannot prove cause and effect. [6] [7] [8]

In a large, nine-center study of 1047 people with AL amyloidosis treated with autologous stem cell transplant between 2010 and 2020, death by day 100 was 3.0% and blood response after transplant was reported in 75.4%. Among people who had not reached the deepest blood response before transplant, responses deepened after transplant in 56.3% of paired assessments, and the median overall survival was 6.3 years with a median follow-up of 5.1 years. Worse survival was linked to older age, higher bone marrow plasma cells, higher pre-transplant abnormal blood marker levels, higher cardiac biomarkers, reduced kidney function, and receiving reduced-dose conditioning. [6]

A separate multicenter study of 475 transplant-eligible patients focused on whether adding high-dose melphalan with autologous transplant within 12 months improved time to progression compared with standard-intensity therapy alone. It reported that high-dose melphalan and daratumumab were each linked to longer time to progression, but the benefit of high-dose melphalan was mainly seen in people who still had measurable disease after standard therapy rather than those already in complete response. The study also reported that higher bone marrow plasma cell burden and a genetic change called 1q gain were linked to earlier progression, and 1q gain remained a risk factor even in people who received transplant. [7]

For advanced amyloid heart disease, a multicenter cohort of 113 heart transplant recipients compared AL amyloidosis with transthyretin (ATTR) amyloidosis and reported similar 5-year survival (83% ATTR vs 77% AL). Infections after transplant were common in both groups (40% ATTR and 43% AL), and sepsis was the leading reported cause of death. In the AL group, blood responses improved after heart transplant, with complete response increasing from 42% before transplant to 54% after transplant, alongside ongoing use of anti-plasma cell treatments. [8]

One case report described a single 45-year-old man with multiple myeloma and cardiac AL amyloidosis who underwent autologous stem cell transplant while using an implantable pulmonary artery pressure sensor to guide fluid pill (diuretic) adjustments during the transplant period. The report states he completed transplant without heart failure worsening and reached complete blood remission, suggesting remote pressure monitoring may be one way to support very close heart and fluid management in complex cases. Because this is one person, it is uncertain how often similar results would occur. [9]

For patients and caregivers, these studies mainly add context about what transplant-centered care has looked like in recent real-world practice, and which pre-transplant features were linked to higher risk or earlier relapse in the studied groups. They also underscore that heart transplantation for amyloid heart disease can be followed by ongoing amyloid-directed treatment, while infections remain a major concern after heart transplant. What remains uncertain is how much each approach changes outcomes compared with other strategies in similar patients, because the evidence here is based on retrospective comparisons and a single-patient report rather than randomized trials. [6] [7] [8] [9]

Across this group of studies, treatments that redirect the immune system to target BCMA (a marker on abnormal plasma cells) showed a consistent pattern of rapid, deep improvements in amyloid-related blood markers in relapsed AL amyloidosis. Some people also had organ improvement, especially in the heart and kidneys, although organ recovery can take time and follow-up was limited in parts of the evidence. The main uncertainty is how durable these responses are over longer periods and how best to balance treatment intensity with infection risk. [10] [11] [12]

In a systematic review pooling 80 patients treated with BCMA-directed bispecific antibodies (teclistamab or elranatamab), most patients had a blood response and many had deep responses, with reported heart and kidney responses as well. Safety issues were frequent, including cytokine release syndrome and a notable rate of serious infections, while nervous system side effects were less common. [10]

In a German multicenter retrospective study of 52 patients given teclistamab, many patients reached very deep blood responses quickly, and organ responses were reported by 6 months for both heart and kidney involvement. Infections were a major cause of serious complications and deaths, and most patients received immunoglobulin replacement therapy, which the study linked with lower risk of severe and fatal infections. Follow-up was relatively short, so longer-term durability and late effects remain unclear. [11]

One case report described a 74-year-old woman with AL amyloidosis linked to a non-IgM lymphoplasmacytic lymphoma who had relapsed after multiple prior treatments and then received investigational BCMA-directed CAR T-cell therapy. She achieved a complete blood response with minimal residual disease negativity, and her kidney measures improved, while heart markers were described as stable. Side effects included manageable cytokine release syndrome and episodes of acute kidney injury, and the report emphasized that longer follow-up is needed to understand how long the benefit lasts. [12]

For patients and caregivers, this month reinforces that BCMA-targeted immune therapies are being actively tested for AL amyloidosis that has returned after other treatments, and they can sometimes produce deep blood responses with some organ improvement reported in the heart and kidneys. At the same time, these studies highlight that infection risk is a central concern, alongside cytokine release syndrome, and some evidence discusses supportive approaches such as immunoglobulin replacement as part of safety management. What remains uncertain is how durable responses are over years, which patients benefit most, and how to minimize serious infections while maintaining disease control. [10] [11] [12]

Across these papers, a consistent message is that monitoring AL amyloidosis depends heavily on the exact testing method used and how results are interpreted. Studies comparing laboratory platforms found that results usually match, but disagreements can cluster near decision cutoffs or when certain medicines interfere with the test signal. [13] [14]

In a large evaluation of 660 serum samples from people with plasma cell disorders (including AL amyloidosis), Diazyme kappa and lambda blood marker tests run on a Roche Cobas system showed strong agreement with the widely used Freelite test, with 96% overall clinical concordance. The main mismatches were close to decision thresholds, meaning small numerical differences could sometimes change how a result is categorized. [13]

In a smaller comparative study of immunofixation electrophoresis (a test used to detect certain abnormal proteins), agreement between two testing systems ranged from 60.0% to 88.5%, and samples from AL amyloidosis patients had the lowest agreement. The HYDRASYS 2 system detected extra bands (often light-chain related) that the Epalyzer 2 Jr. missed, suggesting that test choice can affect whether a low-level abnormal protein is seen. [14]

That same study highlighted a specific monitoring challenge in people receiving daratumumab: the drug can create a band that looks like disease protein on immunofixation. In 9 of 10 daratumumab-treated samples, the IgG kappa band disappeared after a displacement step designed to remove daratumumab signal, and 3 samples became fully negative, showing how drug interference could change test interpretation. [14]

For patients and caregivers, these results help explain why lab reports used to follow AL amyloidosis can differ between hospitals, platforms, or over time, even when the overall clinical picture feels unchanged. Right now, this is mainly background information that can clarify why clinicians sometimes emphasize using the same lab method consistently, and why extra steps may be needed to interpret tests during daratumumab therapy. What remains uncertain is how often these testing differences change real-world decisions in AL amyloidosis, since the studies focused on analytical agreement rather than long-term patient outcomes. [13] [14]

Taken together, these papers suggest that many people are diagnosed after a period of mixed warning signs and incomplete testing, and that expert guidance continues to emphasize tissue confirmation (biopsy) and coordinated assessment across specialties. Real-world electronic health record studies showed that recommended blood and urine testing was often not completed, which can make it harder to sort out AL amyloidosis from other amyloid diseases or to confirm the cause of kidney problems. [15] [16] [17] [18]

In a US database study of suspected AL amyloidosis and suspected wild-type transthyretin amyloid heart disease, only 53% to 66% had any amyloidosis-related test recorded in the 24 months before diagnosis, and complete monoclonal protein testing was uncommon (17% in the AL group). The report also noted that most patients (83% to 85% across groups) did not have complete monoclonal protein testing documented, highlighting gaps in how diagnostic workups are carried out in everyday care. [15]

A separate, very large US health-record study compared diagnoses that appeared before AL amyloidosis versus before wild-type transthyretin amyloidosis. Before AL amyloidosis was diagnosed, people more often had kidney-related problems (including chronic kidney disease and protein in the urine), digestive issues (such as constipation, diarrhea, nausea/vomiting, and swallowing difficulty), nerve problems (polyneuropathy), and prior plasma cell disorders documented, while heart-related diagnoses and carpal tunnel syndrome were more common before wild-type transthyretin amyloidosis. [16]

Two guidance documents reinforced that diagnosis should be biopsy-based when organ involvement is suspected, especially for kidney disease linked to a monoclonal protein, and that assessment is best coordinated through expert, multidisciplinary teams. The European Union guidance for monoclonal gammopathy of renal significance stressed that lack of a detectable monoclonal protein in blood or urine does not rule out these conditions, and it highlighted thorough kidney biopsy review, including specialized testing when needed. [18]

A Brazilian expert consensus also emphasized standardized tissue diagnosis (including Congo red testing) and routine use of blood markers for staging, while noting that access to specific tests and treatments differs between settings. This highlights that the diagnostic journey can be shaped not only by symptoms, but also by what testing is available locally. [17]

For patients, this set of studies helps put common experiences into context: AL amyloidosis can show up through kidney, stomach or bowel, and nerve problems before it is recognized, and real-world testing may be incomplete even when amyloidosis is suspected. These papers do not change what a specific person should do, but they clarify why expert-center evaluation and biopsy-based confirmation are emphasized in professional guidance, and why diagnosis pathways can vary across health systems and countries. Important uncertainties remain because health-record studies cannot reliably show whether every test was truly missed versus done outside the captured system, and they cannot prove which earlier clues would have led to faster diagnosis in an individual. [15] [16] [17] [18]

Across these studies, researchers looked at whether adding specific heart-focused measurements can better flag who is more likely to have dangerous heart problems in AL amyloidosis, either at diagnosis or during treatment. Both papers suggest that certain test results line up with higher risk, but both are exploratory and based on relatively small numbers, so how well they apply to other hospitals and patient groups is still uncertain. [19] [20]

One observational study in South Asian patients found that an abnormal value from a cardiac magnetic resonance imaging (MRI) measurement that estimates how much the heart tissue has been replaced or expanded (extracellular volume) was linked to worse outcomes. In that study, all deaths occurred in the group with abnormal results, and higher values were also seen in people who had sudden cardiac death, although only a small subset had an evaluable scan measurement. [19]

A separate retrospective study looked at predicting cardiovascular side effects in people with multiple myeloma or primary AL amyloidosis receiving proteasome inhibitor therapy (such as bortezomib or carfilzomib). The authors reported that the original baseline risk score they tested did only modestly well, while a model that added an early on-treatment blood marker (NT-proBNP measured before cycle 2), plus age and exposure to carfilzomib, separated higher- and lower-risk patients better within their dataset. The study notes these refinements still need external validation in other centers. [20]

For patients and caregivers, this set of studies mainly adds background on how clinicians and researchers are trying to estimate heart risk more precisely in AL amyloidosis, using a combination of imaging and blood markers at different time points (at diagnosis and early during certain therapies). These results may help guide future research on monitoring and risk prediction, but the evidence here is not yet strong enough to say how reliably these tools will predict outcomes for an individual person across different hospitals, treatments, and patient populations. [19] [20]

Across these studies, the overall pattern was that not all abnormal antibody proteins behave the same way: small differences in their sequence and structure can change how stable they are, how long they last outside cells, and whether they can directly stress organs like the heart. Much of the evidence this month is exploratory and based on lab models or detailed testing of patient samples, so it helps explain possible causes of damage rather than proving what happens in every person. [21] [22] [23] [24] [25]

In a human heart-cell lab model, some amyloidosis-related proteins changed the heart cells' electrical behavior in ways that could plausibly interfere with normal beating. Two amyloid-forming samples reduced the cells' spontaneous firing and the speed of the electrical upstroke, and one sample shortened the action potential duration; one sample also reduced a sodium current by about 40% and changed how a calcium current turned off. In contrast, a comparison protein sample had no clear electrical effects, showing that heart stress can differ by the specific protein involved. [21]

Several papers focused on why some of these proteins may be more or less likely to misfold and form amyloid. Adding certain sugar groups (N-glycosylation) to amyloid-forming kappa proteins made them more compact and stable, reduced their shape changes, and improved secretion and stability outside the cell, which the authors describe as potentially protective in some situations rather than always harmful. Separately, small molecules designed to stabilize lambda proteins reduced their tendency to locally unfold, made them harder for proteases to cut, and delayed amyloid formation in test-tube experiments across multiple different proteins. [22] [24]

One patient-based study used full-length RNA sequencing plus protein testing to map these proteins in more detail and found that changes in the constant region were present in a minority of cases. In 89 people with systemic AL amyloidosis, the sequencing approach detected the monoclonal protein in 95.4% and matched a second sequencing method exactly, and mass spectrometry could detect the protein in blood and in amyloid deposits. Constant-region changes were seen in about 10% of lambda cases and in none of the kappa cases, and computer analyses suggested these changes could either stabilize or destabilize the protein depending on the mutation. [23]

A separate exploratory study examining amyloid taken from patients reported tube-like structures that resembled parts of bacteriophages (viruses that infect bacteria). The authors used cryo-electron microscopy to assign these structures to a phage tail tube protein and discussed that they might co-purify with amyloid fibrils, but they also noted contamination could not be fully ruled out. If real, the observation would suggest that other biological materials may sometimes be present alongside amyloid deposits, with unclear effects on how deposits form or change. [25]

For patients and caregivers, these studies mainly add background on why organ damage and amyloid behavior can vary between individuals even within AL amyloidosis. The heart-cell work supports the idea that some abnormal proteins may directly disturb heart electrical function, while the structure studies show that features like sugar attachments, specific sequence changes, and protein stability can shift how these proteins fold and persist. Most results are early-stage (lab or detailed sample analyses), so they do not yet tell which specific protein features will predict a given person's organ course, and the phage-related finding remains uncertain until confirmed. [21] [22] [23] [24] [25]

This months papers mainly describe unusual ways amyloidosis was recognized (skin lesions, enlarged tongue, or nail changes) and unusual complications affecting the kidneys or bleeding risk. A common thread was that tissue biopsies (skin, tongue, nail unit, or kidney) helped confirm amyloid type or identify a second process happening at the same time. The evidence here is mostly case reports (single patients), so the details may not apply broadly, but they illustrate real-world diagnostic and care challenges. [26] [27] [28] [29] [30] [31]

Several reports showed that amyloidosis can first be suspected from visible or felt changes. One patient had symmetric purplish nodules on the hands along with an enlarged tongue, which led to testing that found multiple myeloma causing AL amyloidosis; symptoms improved after daratumumab-containing therapy. [26]

Two other single-patient reports focused on tongue or nail involvement as the clue that started the workup. In one, abdominal fat biopsy was negative but a tongue biopsy confirmed AL (kappa) amyloid, and both swallowing and lab markers improved after myeloma-directed therapy that later included daratumumab. [27] In another, progressive nail dystrophy led to a nail-unit biopsy that confirmed amyloid; the patient was later found to have advanced heart involvement and died despite treatment, highlighting how delays can matter when the heart is affected. [28]

Kidney biopsies also helped explain unexpected kidney changes and unusual amyloid types. One patient with known AL amyloidosis developed a fast-worsening kidney inflammation pattern (crescentic glomerulonephritis) after COVID-19 vaccination; kidney function did not improve with AL-directed therapy but improved with immune-suppressing treatment, suggesting a second kidney problem separate from amyloid. [29] Another patient with Waldenstrom macroglobulinaemia had a kidney biopsy showing combined heavy- and light-chain amyloid (AHL), confirmed by specialized mass spectrometry, and kidney protein leakage improved over long follow-up after bendamustine and rituximab. [30]

One case report emphasized that not every amyloid diagnosis in someone with a plasma cell condition is AL amyloidosis. A patient had smoldering multiple myeloma plus another blood disorder and kidney-limited ALECT2 amyloidosis confirmed by mass spectrometry, and remained clinically stable over 24 months with monitoring. [31]

For patients and caregivers, these reports are most useful as context: amyloidosis can sometimes show itself in less expected places (tongue, skin, nails) and kidney worsening is not always due to amyloid progression. They also underline why amyloid typing from biopsy tissue (often using advanced lab methods) can matter, because different amyloid types and overlapping conditions may look similar at first but behave differently. What remains uncertain is how often these specific presentations occur and how reliably these patterns predict outcomes, since most data here come from individual cases.

Together, these papers point to two related issues: AL amyloidosis can affect multiple organs more widely than expected, and bleeding or clotting abnormalities can complicate care in uncommon ways. The organ-wide data come from an autopsy series (stronger than single case reports for describing patterns), while the bleeding-related papers are single-patient experiences that may not generalize. [32] [33] [34]

In a retrospective autopsy study of 24 people who had both multiple myeloma and AL amyloidosis, amyloid deposits were often extensive in the heart, lungs, and kidneys, and most cases were the lambda type. AL amyloidosis had been diagnosed before death in 15 of 24 cases, meaning it was not recognized during life in the remaining cases in this series. [32]

One case report focused on bleeding risk during dialysis access surgery in a patient with systemic AL amyloidosis and higher-than-intended blood-thinning levels. Surgeons used an Auersvald hemostatic net (a technique to reduce empty space under the skin) during arteriovenous fistula revision, and the patient did not develop a postoperative hematoma, with dialysis later resumed through the fistula. [33]

Another case report described a different cause of bleeding-related lab abnormalities: severe acquired factor X deficiency in a woman who was later diagnosed with Sjogrens syndrome, with partial improvement in lab values after prednisone. This was presented as the first reported link between Sjogrens syndrome and autoimmune-mediated acquired factor X deficiency, and it occurred without major bleeding symptoms in this patient. [34]

This theme mainly adds background about complications clinicians watch for rather than offering direct takeaways for day-to-day decisions. The autopsy study suggests that when AL amyloidosis occurs alongside multiple myeloma, organ involvement can be widespread and may not always be recognized during life, but it does not show how often this happens in current practice or how it changes with modern care. The two bleeding-related case reports highlight that bleeding risk can come from different sources (surgery plus anticoagulation, or an autoimmune clotting-factor problem), but they are single cases, so it is uncertain how common these situations are.